Bed bugs were likely one of the first pests found in cities, new study finds
Common bed bugs (Cimex lectularius) grew in number when humans started living together in the first cities. These tiny bloodsuckers were likely the first insect pests to thrive in city environments, and maybe even the first urban pests, according to a new study by scientists at Virginia Tech, United States, that was published in Biology Letters on May 28.
Bed bugs originally fed on bats. But around 245,000 years ago, one group of bedbugs started feeding on humans, likely beginning with Neanderthals.
About a year ago, Lindsay Miles from Virginia Tech began studying bedbug genetic data to see how their populations changed over time. Bedbug numbers dropped around 19,000 years ago, when the Ice Age ended and habitats changed.
Both types of bedbugs did decline, but the ones that fed on humans increased sharply some 13,000 years ago, stayed steady for a while, and then rose again 7,000 years ago. In comparison, the population of bedbugs that feed on bats are still decreasing.
The big change from fewer to more bedbugs happened around the same time the first cities appeared in western Asia and started to grow, as per the study. Before that, people moved around a lot and didn't often meet other groups, so bedbugs didn't spread much either.
But once people began living together in cities, it created a new environment for bedbugs. The study states that the bugs started mating with each other more, their numbers grew quickly, and they adapted to life in cities.
The researchers also hypothesised that bed bugs were one of the first pests to adjust to city life and were likely the first insect pests to live in urban areas. Other animals became connected to city life much later. German cockroaches, for instance, started living closely with humans around 2,100 years ago, and black rats around 5,000 years ago.
Mark Ravinet, an evolutionary biologist from the University of Oslo in Norway, who said that these findings showed that bedbugs can help scientists learn how species adapt to live with humans. He said the study was important for understanding how quickly animals can adjust to human environments and what changes they make in order to survive.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
6 hours ago
- Time of India
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy
Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda. The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on experimental cancer treatments and show that its success as Pfizer 's COVID-19 vaccine partner was not a one-off achievement. It also underscores a push across the pharma sector to master a new dual mechanism of action in oncology that activates the immune system - similar to an established drug class including Merck & Co's Keytruda - but which also cuts a tumour's blood supply. BioNTech's German-listed shares surged 16.7% by 1236 GMT to a six-week high. The two companies said in separate statements that the U.S. group will co-develop and co-commercialize BioNTech's drug, BNT327, for multiple solid tumour types. Live Events BioNTech's CEO and co-founder Ugur Sahin said the collaboration will serve "to accelerate and broadly expand BNT327's development to fully realize its potential." The companies said in presentation slides that Bristol Myers was bringing global networks in clinical development and manufacturing to the partnership, among other benefits. BioNTech said in a statement that the partners were seeking to set a new standard of care in the cancer market segment, now dominated by so-called checkpoint inhibitors including Keytruda with $29.5 billion in 2024 sales. Western drugmakers have struck a host of deals to win access to the new drug technology, known as PD-1/VEGF bispecific antibodies, which was pioneered in China. Pfizer last month partnered with China's 3SBio , paying $1.25 billion upfront and up to another $4.8 billion depending on developmental achievements. Merck & Co, whose Keytruda business is under threat from the sector's development push, in November last year licensed an early-stage cancer drug from China-based LaNova Medicines for up to $3.3 billion. "We are now starting to see an industry vote of confidence in the differentiation of this novel mechanism," BMO Capital Markets analysts said in a note. They welcomed BioNTech "partnering with a big pharma name to help manage a broad development plan and potential commercialization". Shares in Instil Bio, which is working with China's ImmuneOnco on a similar compound, soared 24% in U.S. trade on Monday. Summit Therapeutics and China's Akeso have formed another partnership in the development race with a drug candidate called ivonescimab. BioNTech took full ownership of BNT327 through the acquisition of China's Biotheus earlier this year for $800 million upfront and up to $150 million contingent on development achievements. It previously held certain rights in the drug under a 2023 collaboration deal. In addition to an initial payment of $1.5 billion, Bristol plans to pay BioNTech $2 billion in non-contingent anniversary payments through 2028. BioNTech may also earn up to $7.6 billion in development, regulatory and commercial milestones, Bristol said. The companies will share global profits and losses from the drug equally, and joint development and manufacturing costs will also be shared on a 50/50 basis, with some exceptions. BNT327 is being tested as a first-line treatment in extensive stage small cell lung cancer and non-small cell lung cancer. More than 1,000 patients have been treated with the drug to date. Economic Times WhatsApp channel )
Time of India
7 hours ago
- Time of India
The color you see in total darkness has a name, and it's not 'black'
When you close your eyes or sit in pitch darkness, what do you see? Most would instinctively say 'black,' but your brain is telling you something else. That deep, indescribable hue isn't true black—it's something far more unique. It's called Eigengrau , a German word meaning 'intrinsic gray' or 'brain gray,' and it's one of the most curious visual phenomena in the human experience. Eigengrau isn't born from light, shadow, or pigment. It's an illusion—your brain's way of coloring the silence when all external light disappears. Even in absolute darkness, your eyes and brain remain active. Neurons in your retina keep firing at a low rate, producing faint patterns and signals, which your brain interprets as a uniform, dark gray. In this way, Eigengrau is not what we see with our eyes, but what our brains think we're seeing. The Color That Exists Only in Your Mind Unlike any other color, Eigengrau isn't found on a paint chip or in a digital hex code. You can't replicate it because it's not made by mixing hues—it's a visual experience created entirely within your mind. In fact, Eigengrau is unique to each person, shaped by their individual brain chemistry, retinal activity , and perception. Some may experience a darker version, others a touch lighter, occasionally dotted with tiny moving lights or faint static. This " visual noise " has fascinated scientists for centuries. Since the 19th century, researchers have studied how even in complete darkness, the human retina produces random electrical signals that the brain processes as vision. It's a kind of self-made twilight , a liminal space between seeing and not seeing. These spontaneous retinal events—largely caused by the thermal motion of molecules like rhodopsin—create a persistent illusion of faint grayness. In a poetic way, Eigengrau is our mind's refusal to accept total darkness. Astronauts, Stars, and the Science of Not-Seeing What's even more fascinating is how Eigengrau behaves in contrast. In a starry sky, the darkness around the stars appears deeper than Eigengrau because our eyes are wired to notice contrast more than absolute brightness. That's why the night sky can feel darker than the color you see when you close your eyes. You Might Also Like: Purple is a lie: Why your brain invented a colour that does not exist in nature? Scientists reveal Astronauts, in the vast blackness of space, report seeing Eigengrau more vividly than we do on Earth—proof of how the brain continues to fill visual voids, even in the most light-deprived environments. It's not just a color but a survival tool, an evolutionary quirk that keeps our visual system humming even when there's nothing to see. iStock In a starry sky, the darkness around the stars appears deeper than Eigengrau because our eyes are wired to notice contrast more than absolute brightness. (Representational image: iStock) A Shared Phenomenon, a Personal Experience Though nearly universal, Eigengrau is a deeply personal experience. Each brain interprets its own version of darkness, and no two people see it exactly the same. It's a quiet, constant reminder that our minds are always active—interpreting, imagining, and even inventing what isn't there. Eigengrau reminds us that perception isn't just about what enters our eyes—it's about how our brains make sense of it. So next time you find yourself alone in the dark, remember: you're not looking at nothing. You're witnessing one of the most mysterious and intimate shades in the universe. A color that belongs to no one but you, yet is seen by everyone. A color that doesn't exist in the world—but lives entirely in your mind. You Might Also Like: What is your favourite colour? Does it really matter, psychologist reveals
Indian Express
10 hours ago
- Indian Express
Pune University PG entrance exams start from today
The entrance exam for various postgraduate courses at Savitribai Phule Pune University (SPPU) will commence from Tuesday and continue till June 5. The examinations will be conducted in the home-based online proctored mode for a total of 49 courses from various departments. The 100 mark paper will also have a negative marking system. For every wrong answer, one-fourth of the allotted marks of the question will be deducted. Section A of the examination will have questions related to general knowledge, aptitude, logic, comprehension as per the syllabus for a total of 20 marks. Section B of the paper will contain subject specific questions as per the syllabus. In case the candidates secure equal marks in total, candidates securing better marks in section B would be selected. The online exam system can be accessed by students using a mobile phone, laptop, PC, tablet or an l-pad with a working front camera. The exam is only being conducted for the postgraduate programmes for which applications greater than the intake capacity capacity were received. Day one will have entrance examinations for courses like M.A. Philosophy, Botany, Electronic Science, Physics. M.A. in German, M.A. Sociology, and various other courses. On day two, M.A. Economics, Master of Public Health, Media and Communication Studies, M.A. English, M.A. Politics and other exams will be conducted. On day three, M.A. (Gender Culture and Development Studies), & (2 Years), Chemistry, Master of Arts (Journalism and Mass Communication), and other entrance exams will be conducted.
